IPO: NAV growth, strong exits, and major portfolio milestones underpin a robust financial outlook
NAV per share rose to 113.9p, with strong exits and portfolio funding driving a robust balance sheet. Key milestones included a £27m uplift from Pfizer's obesity franchise, major fundraising in quantum, and a successful Centessa exit. FY26 priorities focus on capital vehicles and further exits.Orig…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.